Skip to main content
Erschienen in: Clinical and Translational Oncology 5/2017

31.10.2016 | Research Article

Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer

verfasst von: A. J. Conde-Moreno, G. Herrando-Parreño, R. Muelas-Soria, J. Ferrer-Rebolleda, R. Broseta-Torres, M. P. Cozar-Santiago, F. García-Piñón, C. Ferrer-Albiach

Erschienen in: Clinical and Translational Oncology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine the effectiveness of whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) in detecting metastases by comparing the results with those from choline-positron emission tomography-computed tomography (choline-PET/CT) in patients with biochemical relapse after primary treatment, and no metastases in bone scintigraphy, CT and/or pelvic MRI, or metastatic/oligometastatic prostate cancer (PCa). Patients with this disease profile who could benefit from treatment with stereotactic body radiation therapy (SBRT) were selected and their responses to these techniques were rated.

Materials and methods

This was a prospective, controlled, unicentric study, involving 46 consecutive patients from our centre who presented biochemical relapse after adjuvant, salvage or radical treatment with external beam radiotherapy, or brachytherapy. After initial tests (bone scintigraphy, CT, pelvic MRI), 35 patients with oligometastases or without them were selected. 11 patients with multiple metastases were excluded from the study. WB-DW-MRI and choline-PET/CT was then performed on each patient within 1 week. The results were interpreted by specialists in nuclear medicine and MRI. If they were candidates for treatment with ablative SBRT (SABR), they were then evaluated every three months with both tests.

Results

Choline-PET/CT detected lesions in 16 patients that were not observable using WB-DW-MRI. The results were consistent in seven patients and in three cases, a lesion was observed using WB-DW-MRI that was not detected with choline-PET/CT. The Kappa value obtained was 0.133 (p = 0.089); the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of WB-DW-MRI were estimated at 44.93, 64.29, 86.11, and 19.15%, respectively. For choline-PET/CT patients, the sensitivity, specificity, PPV, and NPV were 97.10, 58.33, 93.06, and 77.78%, respectively.

Conclusions

Choline-PET/CT has a high global sensitivity while WB-DW-MRI has a high specificity, and so they are complementary techniques. Future studies with more enrolled patients and a longer follow-up period will be required to confirm these data. The initial data show that the best technique for evaluating response after SBRT is choline-PET/CT.
Trial registration number NCT02858128.
Literatur
2.
Zurück zum Zitat Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578–83.CrossRefPubMed Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578–83.CrossRefPubMed
3.
6.
Zurück zum Zitat Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St gallen advanced prostate cancer consensus conference (APCCC) 2015. Ann Oncol. 2015;26:1589–604. doi:10.1093/annonc/mdv257.CrossRefPubMedPubMedCentral Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St gallen advanced prostate cancer consensus conference (APCCC) 2015. Ann Oncol. 2015;26:1589–604. doi:10.​1093/​annonc/​mdv257.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Evangelista L, Cimitan M, Zattoni F, Guttilla A, Zattoni F, Saladini G. Comparison between conventional imaging (abdominal–pelvic computed tomography and bone scan) and [18F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate-tohigh-risk prostate cancer: a retrospective analysis. Scand J Urol. 2015;49:345–53. doi:10.3109/21681805.2015.1005665.CrossRefPubMed Evangelista L, Cimitan M, Zattoni F, Guttilla A, Zattoni F, Saladini G. Comparison between conventional imaging (abdominal–pelvic computed tomography and bone scan) and [18F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate-tohigh-risk prostate cancer: a retrospective analysis. Scand J Urol. 2015;49:345–53. doi:10.​3109/​21681805.​2015.​1005665.CrossRefPubMed
8.
Zurück zum Zitat Soyka JD, Muster MA, Schmid DT, Seifert B, Schick U, Miralbell R, et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2012;39:936–43. doi:10.1007/s00259-012-2083-2.CrossRefPubMed Soyka JD, Muster MA, Schmid DT, Seifert B, Schick U, Miralbell R, et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2012;39:936–43. doi:10.​1007/​s00259-012-2083-2.CrossRefPubMed
9.
Zurück zum Zitat Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171:2122–7.CrossRefPubMed Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171:2122–7.CrossRefPubMed
10.
Zurück zum Zitat Hricak H, Choyke P, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007;243:28–53.CrossRefPubMed Hricak H, Choyke P, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007;243:28–53.CrossRefPubMed
11.
Zurück zum Zitat Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, et al. Endorectal magnetic resonance imaging at 1.5 tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol. 2009;19:761–9. doi:10.1007/s00330-008-1174-8.CrossRefPubMed Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, et al. Endorectal magnetic resonance imaging at 1.5 tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol. 2009;19:761–9. doi:10.​1007/​s00330-008-1174-8.CrossRefPubMed
12.
Zurück zum Zitat Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L, et al. Endorectal and dynamic contrast enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol. 2008;190:1187–92. doi:10.2214/AJR.07.3032.CrossRefPubMed Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L, et al. Endorectal and dynamic contrast enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol. 2008;190:1187–92. doi:10.​2214/​AJR.​07.​3032.CrossRefPubMed
13.
Zurück zum Zitat Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. 2008;54:589–600. doi:10.1016/j.eururo.2007.12.034.CrossRefPubMed Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. 2008;54:589–600. doi:10.​1016/​j.​eururo.​2007.​12.​034.CrossRefPubMed
14.
Zurück zum Zitat Panebianco V, Barchetti F, Sciarra A, Musio D, Forte V, Gentile V, et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multiparametric magnetic resonance imaging. Eur Radiol. 2013;23:1745–52. doi:10.1007/s00330-013-2768-3.CrossRefPubMed Panebianco V, Barchetti F, Sciarra A, Musio D, Forte V, Gentile V, et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multiparametric magnetic resonance imaging. Eur Radiol. 2013;23:1745–52. doi:10.​1007/​s00330-013-2768-3.CrossRefPubMed
15.
Zurück zum Zitat Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d’Othée BJ, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol. 2007;1(25):3281–7.CrossRef Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d’Othée BJ, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol. 2007;1(25):3281–7.CrossRef
16.
Zurück zum Zitat Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline better CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014;55:223–32. doi:10.2967/jnumed.113.123018.CrossRefPubMed Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline better CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014;55:223–32. doi:10.​2967/​jnumed.​113.​123018.CrossRefPubMed
17.
Zurück zum Zitat Schilling D, Schlemmer HP, Wagner PH, Böttcher P, Merseburger AS, Aschoff P, et al. Histological verification of 11C choline positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 2008;102:446–51. doi:10.1111/j.1464-410X.2008.07592.x.CrossRefPubMed Schilling D, Schlemmer HP, Wagner PH, Böttcher P, Merseburger AS, Aschoff P, et al. Histological verification of 11C choline positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 2008;102:446–51. doi:10.​1111/​j.​1464-410X.​2008.​07592.​x.CrossRefPubMed
19.
Zurück zum Zitat Rinnab L, Mottaghy FM, Simon J, Volkmer BG, de Petriconi R, Hautmann RE, et al. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int. 2008;81:191–7. doi:10.1159/000144059.CrossRefPubMed Rinnab L, Mottaghy FM, Simon J, Volkmer BG, de Petriconi R, Hautmann RE, et al. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int. 2008;81:191–7. doi:10.​1159/​000144059.CrossRefPubMed
20.
Zurück zum Zitat Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423–9. doi:10.1016/j.eururo.2007.03.032.CrossRefPubMed Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423–9. doi:10.​1016/​j.​eururo.​2007.​03.​032.CrossRefPubMed
21.
Zurück zum Zitat Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate Cancer: a meta-analysis. Clin Radiol. 2008;63:387–95. doi:10.1016/j.crad.2007.05.022 DOI: 18325358.CrossRefPubMed Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate Cancer: a meta-analysis. Clin Radiol. 2008;63:387–95. doi:10.​1016/​j.​crad.​2007.​05.​022 DOI: 18325358.CrossRefPubMed
22.
Zurück zum Zitat Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed
23.
Zurück zum Zitat Beheshti M, Vali R, Waldenberger P, F Fitz, Nader M, Hammer J, et al. The use of F-18 to be PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2009;11:446–54. doi:10.1007/s11307-009-0217-0.CrossRefPubMed Beheshti M, Vali R, Waldenberger P, F Fitz, Nader M, Hammer J, et al. The use of F-18 to be PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2009;11:446–54. doi:10.​1007/​s11307-009-0217-0.CrossRefPubMed
25.
Zurück zum Zitat Piccardo A, Paparo F, Piccazzo R, Naseri M, Ricci P, Marziano A, et al. Value of fused 18F choline PET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: preliminary results. Biomed Res Int. 2014; doi:10.1155/2014/103718. Piccardo A, Paparo F, Piccazzo R, Naseri M, Ricci P, Marziano A, et al. Value of fused 18F choline PET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: preliminary results. Biomed Res Int. 2014; doi:10.​1155/​2014/​103718.
26.
Zurück zum Zitat Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by (11C)choline positron emission tomography/computed tomography. Eur Urol. 2011;60:935–43. doi:10.1016/j.eururo.2011.07.060.CrossRefPubMed Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by (11C)choline positron emission tomography/computed tomography. Eur Urol. 2011;60:935–43. doi:10.​1016/​j.​eururo.​2011.​07.​060.CrossRefPubMed
27.
Zurück zum Zitat Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;6:44. doi:10.1186/1748-717X-6-44.CrossRefPubMedPubMedCentral Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;6:44. doi:10.​1186/​1748-717X-6-44.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Picchio M, Berardi G, Fodor A, Busnardo E, Crivellaro C, Giovacchini G, et al. (11)C-choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2014;41:1270–9. doi:10.1007/s00259-014-2734-6.CrossRefPubMed Picchio M, Berardi G, Fodor A, Busnardo E, Crivellaro C, Giovacchini G, et al. (11)C-choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2014;41:1270–9. doi:10.​1007/​s00259-014-2734-6.CrossRefPubMed
29.
Zurück zum Zitat Fisher CG, CP DiPaola, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the spine oncology study group. Spine. 2010;35(22):E1221–9. doi:10.1097/BRS.0b013e3181e16ae2.CrossRefPubMed Fisher CG, CP DiPaola, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the spine oncology study group. Spine. 2010;35(22):E1221–9. doi:10.​1097/​BRS.​0b013e3181e16ae2​.CrossRefPubMed
30.
Zurück zum Zitat Sánchez-Jurado R, Devis M, Sanz R, Aguilar JE, del Puig Cózar M, Ferrer-Rebolleda J. Whole-Body PET/CT studies with lowered 18F-FDG doses: the influence of body mass index in dose reduction. J. Nucl. Med. Technol. 2014;42:62–7. doi:10.2967/jnmt.113.130393.CrossRefPubMed Sánchez-Jurado R, Devis M, Sanz R, Aguilar JE, del Puig Cózar M, Ferrer-Rebolleda J. Whole-Body PET/CT studies with lowered 18F-FDG doses: the influence of body mass index in dose reduction. J. Nucl. Med. Technol. 2014;42:62–7. doi:10.​2967/​jnmt.​113.​130393.CrossRefPubMed
33.
Zurück zum Zitat Luboldt W, Küfer R, Blumstein N, Toussaint TL, Kluge A, Seemann MD, et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology. 2008;249(3):1017–25. doi:10.1148/radiol.2492080038.CrossRefPubMed Luboldt W, Küfer R, Blumstein N, Toussaint TL, Kluge A, Seemann MD, et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology. 2008;249(3):1017–25. doi:10.​1148/​radiol.​2492080038.CrossRefPubMed
34.
Zurück zum Zitat Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol. 2011;60:125–30. doi:10.1016/j.eururo.2011.01.015.CrossRefPubMed Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol. 2011;60:125–30. doi:10.​1016/​j.​eururo.​2011.​01.​015.CrossRefPubMed
35.
Zurück zum Zitat Eiber M, Holzapfel K, Ganter C, Epple K, Metz S, Geinitz H, et al. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J Magn Reson Imaging. 2011;33:1160–70. doi:10.1002/jmri.22542.CrossRefPubMed Eiber M, Holzapfel K, Ganter C, Epple K, Metz S, Geinitz H, et al. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J Magn Reson Imaging. 2011;33:1160–70. doi:10.​1002/​jmri.​22542.CrossRefPubMed
36.
Zurück zum Zitat Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate Cancer: a meta-analysis. Skeletal Radiol. 2014;43:1503–13. doi:10.1007/s00256-014-1903-9.CrossRefPubMed Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate Cancer: a meta-analysis. Skeletal Radiol. 2014;43:1503–13. doi:10.​1007/​s00256-014-1903-9.CrossRefPubMed
37.
38.
Zurück zum Zitat Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P, et al. [18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. Radiat Oncol. 2016;11:9. doi:10.1186/s13014-016-0586-x.CrossRefPubMedPubMedCentral Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P, et al. [18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. Radiat Oncol. 2016;11:9. doi:10.​1186/​s13014-016-0586-x.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Ost P, Jereczek-Fossa BA, As NV, Zilli T, Muacevic A, Olivier K, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69:9–12. doi:10.1016/j.eururo.2015.07.004.CrossRefPubMed Ost P, Jereczek-Fossa BA, As NV, Zilli T, Muacevic A, Olivier K, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69:9–12. doi:10.​1016/​j.​eururo.​2015.​07.​004.CrossRefPubMed
40.
Zurück zum Zitat Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20. doi:10.1007/s00259-013-2525-5.CrossRefPubMed Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20. doi:10.​1007/​s00259-013-2525-5.CrossRefPubMed
41.
Zurück zum Zitat Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68 Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90. doi:10.2967/jnumed.115.160382.CrossRefPubMed Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68 Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90. doi:10.​2967/​jnumed.​115.​160382.CrossRefPubMed
42.
Zurück zum Zitat Maurer, T. et al. PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2015;33(15_suppl):5023. Maurer, T. et al. PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2015;33(15_suppl):5023.
43.
Zurück zum Zitat Maurer, T. et al. PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA. J Clin Oncol. 2015;33(suppl):e16038. Maurer, T. et al. PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA. J Clin Oncol. 2015;33(suppl):e16038.
44.
Zurück zum Zitat Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, et al. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate. 2014;74:297–305. doi:10.1002/pros.22750.CrossRefPubMed Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, et al. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate. 2014;74:297–305. doi:10.​1002/​pros.​22750.CrossRefPubMed
45.
Zurück zum Zitat Ferrer Albiach C, Conde Moreno AJ, Albert Antequera M, et al. Bioclínic retrospective observational study of profiling of mRNAs in patients with cancer próstate oligo-metastases and oligorecurrence. Radiotherapy Oncology Hospital Provincial de Castellón (EudraCT number: 2015-005620-26). Ferrer Albiach C, Conde Moreno AJ, Albert Antequera M, et al. Bioclínic retrospective observational study of profiling of mRNAs in patients with cancer próstate oligo-metastases and oligorecurrence. Radiotherapy Oncology Hospital Provincial de Castellón (EudraCT number: 2015-005620-26).
Metadaten
Titel
Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer
verfasst von
A. J. Conde-Moreno
G. Herrando-Parreño
R. Muelas-Soria
J. Ferrer-Rebolleda
R. Broseta-Torres
M. P. Cozar-Santiago
F. García-Piñón
C. Ferrer-Albiach
Publikationsdatum
31.10.2016
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 5/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1563-4

Weitere Artikel der Ausgabe 5/2017

Clinical and Translational Oncology 5/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.